Chronic pain is more than a sensory issue. It affects cognition in profound ways. This week’s review examines a newly published synthesis by Guerra-Armas et al. (2025), which explores an often-overlooked consequence of chronic pain: neurocognitive impairment. Deficits in attention, executive function, memory and body perception not only impact quality of life but also limit adherence to treatment and the success of rehabilitation.
What’s novel here is the focus on Extended Reality (XR), especially virtual reality, as a therapeutic tool not just for passive distraction, but for active neurocognitive training. This hybrid narrative-systematic review synthesizes 23 studies to examine how XR may support brain function in individuals with chronic pain.
🔗 Dive deeper into the guideline here: https://doi.org/10.3390/healthcare13111338
🧠 What does XR really add?
While XR has shown modest-to-strong effects in reducing pain intensity, its potential to target cognitive deficits is underutilized. The authors argue that immersive environments allow for:
– Dual-task training (motor + cognitive tasks)
– Gamified exercises that improve motivation and adherence
– Ecological validity with scenarios that mirror real-life challenges
– Multisensory stimulation potentially enhancing neuroplasticity
Interestingly, benefits were reported across multiple cognitive domains: from executive function and attention to body perception and emotional regulation. The evidence, though still preliminary, supports XR’s role in reducing pain interference and improving cognitive functioning.
🏥 Clinical implications and barriers to implementation
The authors offer a realistic assessment of the current gap between research and routine use of XR in chronic pain rehabilitation. Despite the growing interest and availability of commercial solutions, such as Enhance® or Reflexion GO VR®, the field still faces considerable implementation barriers. These include the high cost of hardware and software, the limited availability of scientifically validated XR programs specifically designed for neurocognitive rehabilitation, and the absence of standardized protocols for clinical use. Moreover, issues such as unfamiliarity with XR technologies among professionals, concerns about adverse effects like cybersickness, and the lack of sustainable funding models continue to limit adoption in healthcare settings.
The authors emphasize that XR should not be viewed as a substitute for conventional therapy, but rather as a complementary tool within multimodal and personalized treatment strategies. Notably, the review underscores that many XR systems are becoming more user-friendly and accessible, with some offering short, targeted cognitive exercises suitable for daily clinical use. Still, methodological limitations in existing studies, such as small sample sizes, heterogeneity in dosimetry and unclear reporting of training components, pose challenges for widespread clinical integration.
To move forward, the review encourages closer collaboration with stakeholders, improved design of XR software tailored to neurocognitive targets, and the development of rigorous reporting standards, including the use of TIDieR and CONSORT frameworks. While RATE-XR is not referenced in the review, it may serve as a valuable complement. Developed in 2023, RATE-XR offers specific guidance for the reporting and evaluation of therapeutic XR interventions, covering areas such as usability, safety, and patient-centered outcomes (https://doi.org/10.1016/j.jmir.2023.04.006).
🎯 From Review to Real-World Integration
The approach described in this review aligns closely with the broader strategy we follow across our XR initiatives at BSA. Whether addressing chronic pain, supporting cognitive rehabilitation or improving emotional well-being, we integrate XR into established care pathways, always linked to specific therapeutic goals.
The authors support this model and highlight the same priorities we encounter in practice: the need for rigorous methodology, clearer dosimetry, standardized cognitive outcomes and direct comparisons with conventional interventions. These challenges shape our own transition from early pilots to broader clinical use and reinforce the importance of building evidence that is both solid and context-sensitive.
🧭 Final thought
Guerra-Armas et al. don’t overpromise. Their message is cautious: XR-based neurocognitive training is promising but not yet proven. Still, for those of us working on immersive rehab interventions, it offers a roadmap for expanding from analgesia toward cognitive empowerment.
Let’s keep our simulations smart, our designs evidence-based and our expectations realistic.
#SundayResearchDive #ExtendedReality #NeurocognitiveTraining #ChronicPain #DigitalTherapeutics #XRinHealthcare
This article was originally published on vrforhealth